Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto.
Gunter Von Minckwitz
No relevant relationships to disclose
Eric Hahnen
No relevant relationships to disclose
Peter A. Fasching
Consultant or Advisory Role - Genomic Health; Novartis; Roche
Honoraria - Genomic Health; Novartis; Roche
Research Funding - Amgen; Novartis
Jan Hauke
No relevant relationships to disclose
Andreas Schneeweiss
Consultant or Advisory Role - Celgene; Medac; Roche
Honoraria - AstraZeneca; Celgene; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche
Research Funding - Celgene; Roche
Christoph Salat
No relevant relationships to disclose
Mahdi Rezai
No relevant relationships to disclose
Jens U. Blohmer
No relevant relationships to disclose
Dirk Michael Zahm
No relevant relationships to disclose
Christian Jackisch
No relevant relationships to disclose
Bernd Gerber
No relevant relationships to disclose
Peter Klare
No relevant relationships to disclose
Sherko Kummel
Consultant or Advisory Role - Roche
Honoraria - Celgene; Genomic Health; Novartis
Research Funding - Roche
Holger Eidtmann
No relevant relationships to disclose
Stefan Paepke
No relevant relationships to disclose
Valentina Nekljudova
No relevant relationships to disclose
Sibylle Loibl
Consultant or Advisory Role - Roche
Honoraria - Roche; Teva
Michael Untch
No relevant relationships to disclose
Rita K. Schmutzler
No relevant relationships to disclose